Opportunity Information: Apply for DARPA 13 03
Apply for DARPA 13 03
- The DARPA Defense Sciences Office in the science and technology and other research and development sector is offering a public funding opportunity titled "Autonomous Diagnostics to Enable Prevention and Therapeutics Prophylactic Options to Environmental and Contagious Threats (ADEPT PROTECT)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.910 Research and Technology Development.
- This funding opportunity was created on Nov 21, 2012 and posted on Nov 1, 2012.
- Applicants must submit their applications by Jan 15, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The ADEPT PROTECT opportunity (DARPA BAA 13-03) was a Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office solicitation focused on fast, flexible medical countermeasures against environmental and contagious biological threats. The central aim was to support research and development of nucleic acid-based platforms that could be administered to adults and work inside the body (in vivo) to drive short-lived, or transient, production of immune prophylaxis. In practical terms, DARPA was looking for technologies that could rapidly confer temporary protective immunity without relying on the slower timelines associated with conventional vaccine development and manufacturing. This effort sat under the broader Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program, which emphasized the ability to quickly respond to emerging threats with adaptable, platform-style solutions.
The technical idea behind the solicitation was to use nucleic acids as an information carrier that instructs host cells to produce protective molecules for a limited period. Rather than delivering a pre-made biologic in a traditional way, the platform concept implied a "deployable blueprint" approach: administer a nucleic acid construct and allow the body to produce the prophylactic agent on demand. The word "transient" is important because it signals a design goal of temporary expression, potentially reducing long-term exposure and enabling repeated or rapidly updated use when the threat landscape changes. The solicitation language also highlights prophylaxis for adults specifically, indicating the targeted population for the intended countermeasure capability.
From an administrative and funding standpoint, the opportunity was categorized as discretionary funding and supported multiple potential award instruments, including cooperative agreements, grants, other transactions, and procurement contracts. That mix is typical for DARPA announcements and reflects the agency's flexibility in structuring relationships depending on the maturity of the effort, the intended deliverables, and the level of government involvement during execution. The activity category was science and technology and other research and development, and the CFDA listing included 12.910 (Research and Technology Development). There was no cost-sharing or matching requirement stated in the summary information provided.
Eligibility was described as unrestricted, meaning proposals were open to any type of entity, subject to any clarifications contained in the full text of the announcement. In general, that kind of eligibility language is meant to encourage participation from a broad range of performers such as universities, nonprofit research institutes, small businesses, large industry, and other qualified organizations, as long as they can meet the requirements laid out in the BAA.
Key dates in the posting record show the opportunity was posted on November 1, 2012, with a creation date of November 21, 2012. The original and current closing date were both January 15, 2013, and the archive date was March 15, 2013, indicating the solicitation is no longer active. The Additional Information link pointed to the full announcement text, "DARPA BAA 13-03," which would have contained the detailed technical areas of interest, submission instructions, evaluation criteria, and any compliance requirements. For access problems, the listed point of contact was the DARPA BAA Coordinator within the Defense Sciences Office.
Overall, ADEPT PROTECT can be summarized as a DARPA effort to fund R and D on in vivo nucleic acid delivery and expression systems aimed at rapidly generating short-term immune protection in adults, with the broader strategic goal of enabling quicker, more adaptable responses to biological threats than traditional countermeasure pipelines typically allow.
Frequently Asked Questions (FAQs) - ADEPT PROTECT (DARPA BAA 13-03)
What is the ADEPT PROTECT opportunity (DARPA BAA 13-03)?
ADEPT PROTECT (DARPA BAA 13-03) was a Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office solicitation focused on research and development of fast, flexible medical countermeasures against environmental and contagious biological threats.
What was the main goal of ADEPT PROTECT?
The central aim was to support nucleic acid-based platforms that could be administered to adults and work inside the body (in vivo) to drive short-lived (transient) production of immune prophylaxis, enabling temporary protective immunity faster than conventional vaccine development and manufacturing timelines.
Which DARPA office managed this solicitation?
The solicitation was managed within DARPA's Defense Sciences Office.
How does this approach differ from traditional vaccines or biologics?
Rather than delivering a pre-made biologic or relying on the longer timelines typical of conventional vaccine development and manufacturing, the platform concept focused on delivering nucleic acids as an information carrier so host cells produce protective molecules for a limited period after administration.
What does "in vivo" mean in the context of this opportunity?
In vivo indicates the technology was intended to function inside the body after administration, driving expression of a prophylactic agent within the recipient rather than producing the agent externally and then administering it as a finished product.
What does "transient" mean in the context of ADEPT PROTECT?
"Transient" refers to short-lived, temporary expression of the protective molecules produced by the body after receiving the nucleic acid construct. The design goal emphasized temporary expression rather than long-term or permanent activity.
Who was the intended population for the countermeasure capability?
The solicitation highlighted prophylaxis for adults specifically, indicating adults were the targeted population for the intended capability.
What kinds of threats was ADEPT PROTECT intended to address?
The effort was described as targeting environmental and contagious biological threats, with an emphasis on responding quickly to emerging threats.
How does ADEPT PROTECT relate to the broader ADEPT program?
ADEPT PROTECT sat under the broader Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program, which emphasized rapid response to emerging threats using adaptable, platform-style solutions.
What type of funding opportunity was this?
The opportunity was categorized as discretionary funding.
What award instruments were available under this solicitation?
The summary information indicated DARPA could use multiple award instruments, including cooperative agreements, grants, other transactions, and procurement contracts.
Why would DARPA use multiple types of award instruments?
The announcement reflected DARPA's flexibility in structuring awards depending on factors such as the maturity of the effort, intended deliverables, and the level of government involvement during execution.
What was the activity category for ADEPT PROTECT?
The activity category was science and technology and other research and development.
What CFDA listing was associated with this opportunity?
The CFDA listing included 12.910 (Research and Technology Development).
Was cost sharing or matching required?
No cost-sharing or matching requirement was stated in the summary information provided.
Who was eligible to apply?
Eligibility was described as unrestricted, meaning proposals were open to any type of entity, subject to any clarifications in the full text of the announcement.
Does "unrestricted eligibility" mean any organization could submit?
Based on the summary, unrestricted eligibility was intended to encourage participation from a broad range of performers (for example, universities, nonprofit research institutes, small businesses, and large industry), as long as they could meet the requirements laid out in the BAA.
When was the opportunity posted?
The posting record shows it was posted on November 1, 2012.
What was the creation date listed for the opportunity?
The creation date listed was November 21, 2012.
What was the closing date for submissions?
The original and current closing date were both January 15, 2013.
Is this solicitation still open?
No. The archive date was March 15, 2013, indicating the solicitation is no longer active.
Where could applicants find the full technical requirements and submission instructions?
The Additional Information link pointed to the full announcement text, "DARPA BAA 13-03," which would have contained the detailed technical areas of interest, submission instructions, evaluation criteria, and any compliance requirements.
Who was listed as the point of contact for access problems?
For access problems, the listed point of contact was the DARPA BAA Coordinator within the Defense Sciences Office.
What is a simple summary of ADEPT PROTECT?
It was a DARPA R&D effort to fund in vivo nucleic acid delivery and expression systems designed to rapidly generate short-term immune protection in adults, supporting quicker and more adaptable responses to biological threats than traditional countermeasure pipelines typically allow.
Browse more opportunities from the same agency: DARPA Defense Sciences Office
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: RFP FY13 Afghan Project 1 Baghlan Announcement
Previous opportunity: Provide technical assistance and acquire, refine, analyze, and summarize data for the USFWSs Comprehensive Assessment and Monitoring Program requirementss pursuant to the Central Valley Project Improvement Act
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for DARPA 13 03
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (DARPA 13 03) also looked into and applied for these:
| Funding Opportunity |
|---|
| Tranexamic Acid Clinical Research Apply for W81XWH 12 CCCJPC TACR Funding Number: W81XWH 12 CCCJPC TACR Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: $4,000,000 |
| Platelet Storage Technologies Apply for W81XWH 12 CCCJPC PST Funding Number: W81XWH 12 CCCJPC PST Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: $800,000 |
| Emerging Frontiers in Research and Innovation (EFRI) Apply for 12 583 Funding Number: 12 583 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $2,000,000 |
| Division of Molecular and Cellular Biosciences Investigator initiated research projects Apply for 13 510 Funding Number: 13 510 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Division of Integrative Organismal Systems Apply for 13 506 Funding Number: 13 506 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Exploiting Parallelism and Scalability Apply for 13 507 Funding Number: 13 507 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $750,000 |
| Theoretical and Computational Astrophysics Networks Apply for 13 512 Funding Number: 13 512 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Center of Excellence (CoE) in Guided Wave Infrared Sources Apply for FOA RQKS 2013 02 Funding Number: FOA RQKS 2013 02 Agency: Air Force Research Lab Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Long Term Resource Monitoring Program FY 2013 Apply for G13AS00010 Funding Number: G13AS00010 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Continental Scientific Drilling Coordination Office for the Division of Earth Sciences Apply for 13 514 Funding Number: 13 514 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $750,000 |
| Promoting Research and Innovation in Methodologies for Evaluation Apply for 13 515 Funding Number: 13 515 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $800,000 |
| Climate Change Education Partnership Alliance Office (CCEPA Office) Apply for 13 513 Funding Number: 13 513 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Mechanics of Materials Apply for PD 13 1630 Funding Number: PD 13 1630 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Historically Black Colleges and Universities Undergraduate Program Apply for 13 516 Funding Number: 13 516 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $3,000,000 |
| EXPLORATION TECHNOLOGY DEMONSTRATION AND NATIONAL LAB UTILIZATION ENHANCEMENTS Apply for NNJ13ZBG001N Funding Number: NNJ13ZBG001N Agency: NASA Johnson Space Center Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Electronic Warfare Technology Apply for ONRBAA13 005 Funding Number: ONRBAA13 005 Agency: Office of Naval Research Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Plant Feedstock Genomics for Bioenergy A Joint Research Funding Opportunity Announcement USDA, DOE Apply for DE FOA 0000770 Funding Number: DE FOA 0000770 Agency: Office of Science Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Integrated NSF Support Promoting Interdisciplinary Research and Education Apply for 13 518 Funding Number: 13 518 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $3,000,000 |
| Major Research Instrumentation Program Apply for 13 517 Funding Number: 13 517 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $4,000,000 |
| Cooperative Ecosystem Studies Unit, North Atlantic Coast CESU Apply for G13AS00011 Funding Number: G13AS00011 Agency: Geological Survey Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "DARPA 13 03", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.